TD Cowen analyst Josh Jennings maintained a Buy rating on Stereotaxis (STXS – Research Report) yesterday and set a price target of $5.00.
Josh Jennings has given his Buy rating due to a combination of factors including Stereotaxis’s solid financial performance and promising future outlook. The company’s revenue for the fourth quarter was in line with expectations, showing a significant increase compared to the previous year, and it maintained a healthy gross margin. Additionally, Stereotaxis has made strategic advancements with its recent 510(k) submissions for new robotic catheter technologies, which are expected to open up new applications in various medical fields.
Looking forward, Stereotaxis anticipates double-digit revenue growth in 2025, driven by an expanding portfolio of catheters and stable system revenue. The company is also on track to reduce its cash usage, supported by growing recurring revenue and stable operating expenses. With a strong balance sheet and no debt, Stereotaxis is well-positioned to fund its product ecosystem and drive profitable growth. These factors, combined with regulatory achievements and planned commercial launches, contribute to a positive growth outlook for 2026.
According to TipRanks, Jennings is a 4-star analyst with an average return of 3.7% and a 49.09% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, Vericel, and Alphatec Holdings.
In another report released on March 4, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.